Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.54 |
| ▸ | CTSL | P07711 | 16/20 | 0.54 |
| ▸ | CTSS | P25774 | 15/20 | 0.54 |
| ▸ | CTSB | P07858 | 7/20 | 0.54 |
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4037337 | 1.00 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096789 | 0.89 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5096782 | 0.89 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL29590366 | 0.89 | CTSL (0.48) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL14342619 | 0.89 | CTSL (0.48) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5581546 | 0.89 | CTSL (0.48) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5105990 | 0.86 | CTSK (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5105986 | 0.86 | CTSK (0.55) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099597 | 0.85 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL5099601 | 0.85 | CTSK (0.54) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303139-A1 | TARGETING PRIMARY CILIA TO TREAT GLAUCOMA | UNIV INDIANA RES & TECH CORP (US) | 2016-10-20 | — | — | US | claimed |
| US-20150231148-A1 | TARGETING PRIMARY CILIA TO TREAT GLAUCOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-20 | — | — | US | claimed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | claimed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| US-20240156728-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING CO INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4008326-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | Pulmatrix Operating Company, Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11173115-B2 | Monovalent metal cation dry powders for inhalation | PULMATRIX OPERATING COMPANY, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3470057-B1 | CATIONIC DRY POWDERS COMPRISING MAGNESIUM SALT | PULMATRIX OPERATING CO INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210121399-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX OPERATING COMPANY, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10806871-B2 | Inhalable dry powders | PULMATRIX OPERATING COMPANY, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200261667-A1 | INHALABLE DRY POWDERS | PULMATRIX OPERATING COMPANY, INC. | 2020-08-20 | — | — | US | disclosed |
| US-20150136130-A1 | INHALABLE DRY POWDERS | PULMATRIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20140336159-A1 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS | PULMATRIX, INC. | 2014-11-13 | — | — | US | disclosed |
| US-20130266653-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | PULMATRIX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130243828-A1 | CATIONIC DRY POWDERS | PULMATRIX, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266653-A1 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION | KCNN1, KCNN3, KCNN2 | CTSK 2112/4885CTSL 3379/4885CTSS 2619/4885 |
| US-20140336159-A1 | METHODS FOR TREATING AND DIAGNOSING RESPIRATORY TRACT INFECTIONS | TLR3, TLR1, TLR4 | CTSK 380/4885CTSL 82/4885CTSS 365/4885 |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | CTSK 410/4885CTSL 718/4885CTSS 492/4885 |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | CTSK 731/4885CTSL 593/4885CTSS 787/4885 |
| US-20130243828-A1 | CATIONIC DRY POWDERS | CA2, ORAI1, TRPV5 | CTSK 446/4885CTSL 463/4885CTSS 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.